Abstract
PeanuT (Arachis Hypogaea) allergen powder-dnfp (PTAH; previously known as AR101) is a once-daily oral immunotherapy recently approved by the FDA (PALFORZIA™) to mitigate allergic reactions following accidental peanut exposure in peanut-allergic individuals aged 4-17 years. Longer-term data will further characterize the PTAH adverse event (AE) profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
